Immunostimulatory DNA sequences and cancer therapy

Springer Seminars in Immunopathology

Volumn 22, Issue 1-2, 2000, Pages 107-116

  Weiner, G J ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER THERAPY; CELL MEDIATED CYTOTOXICITY; CYTOLYSIS; DNA DETERMINATION; DNA SEQUENCE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IMMUNOTHERAPY; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; TUMOR REGRESSION;

EID: 0033749405     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002810000022     Document Type: Review

References (59)

1. Effective adjuvants for the induction of antigen-specific delayed type hypersensitivity
2. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA
3. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer
4. Treatment of a murine B-cell lymphoma with monoclonal antibodies and IL-2
5. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice
6. Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12
7. Antimetastatic activity induced by Clostridium butyricum and characterization of effector cells
8. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
9. Modulating the immune response to genetic immunization
10. The treatment of malignant tumors by repeated inoculations of Erysipelas with a report of ten original cases
11. Treatment of inoperable malignant tumors with the toxins of Erysipelas and the bacillus Prodigiosus
12. Bacterial DNA induces NK cells to produce IFN-γ in vivo and increases the toxicity of lipopolysaccharides
13. CpG DNA is a potent adjuvant in mice immunized with recombinant hepatitis B surface antigen
14. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells
15. Loss of T-cell receptor ζ-chain and p56(lck) in T-cells infiltrating human renal cell carcinoma
16. Priming of cytotoxic T lymphocytes by DNA vaccines: Requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes
17. Immunotherapy of cancer with genetically modified tumor vaccines
18. Immunotherapy of cancer with dendritic-cell-based vaccines
19. Dendritic cells hold promise for immunotherapy
20. From dendritic cells to tumour vaccines
21. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
22. Cytokine combinations in immunotherapy for solid tumors - A review
23. Cancer vaccines - Challenges and potential solutions
24. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate
25. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
26. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long term results of a clinical trial
27. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA
28. Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine
29. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy
30. CpG motifs in bacterial DNA trigger direct B-cell activation
31. Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs
32. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants
33. Immunostimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines
34. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor
35. Ganglioside vaccines with emphasis on GM2
36. Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer
37. Dendritic cell based therapy of cancer
38. New treatment options for patients with melanoma: Review of melanoma-derived T-cell epitope-based peptide vaccines
39. Idec-C2b8 (Rituximab) anti-Cd20 monoclonal antibody therapy patients with relapsed low-grade non-Hodgkin's lymphoma
40. Active specific immunization in the treatment of patients with melanoma
41. Immunotherapy using dendritic cells picks up steam
42. Immunotherapy of cancer using dendritic cells
43. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma
44. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
45. Induction of antitumor immunity by an anti-idiotype antibody mimicking carcinoembryonic antigen
46. A new foreign policy: MHC class I molecules monitor the outside world
47. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2
48. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
49. + cytotoxic T-lymphocyte responses in vivo
50. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2
51. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model
52. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells
53. DNA vaccination for cancer treatment
54. Dendritic cells and immune-based therapies
55. DNA immunization induces protective immunity against B-cell lymphoma
56. Toward the development of DNA vaccines
57. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
58. Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
59. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma